HK1091141A1 - Compositions and methods for restoring sensitivity to treatment with her2 antagonists - Google Patents

Compositions and methods for restoring sensitivity to treatment with her2 antagonists

Info

Publication number
HK1091141A1
HK1091141A1 HK06112976.7A HK06112976A HK1091141A1 HK 1091141 A1 HK1091141 A1 HK 1091141A1 HK 06112976 A HK06112976 A HK 06112976A HK 1091141 A1 HK1091141 A1 HK 1091141A1
Authority
HK
Hong Kong
Prior art keywords
compositions
treatment
methods
restoring sensitivity
her2 antagonists
Prior art date
Application number
HK06112976.7A
Other languages
English (en)
Inventor
Ginette Serrero
Original Assignee
A & G Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & G Pharmaceutical Inc filed Critical A & G Pharmaceutical Inc
Publication of HK1091141A1 publication Critical patent/HK1091141A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK06112976.7A 2003-08-01 2006-11-27 Compositions and methods for restoring sensitivity to treatment with her2 antagonists HK1091141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49153603P 2003-08-01 2003-08-01
US54779104P 2004-02-27 2004-02-27
PCT/US2004/024593 WO2005011590A2 (en) 2003-08-01 2004-07-30 Compositions and methods for restoring sensitivity to treatment with her2 antagonists

Publications (1)

Publication Number Publication Date
HK1091141A1 true HK1091141A1 (en) 2007-01-12

Family

ID=34118869

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06112976.7A HK1091141A1 (en) 2003-08-01 2006-11-27 Compositions and methods for restoring sensitivity to treatment with her2 antagonists

Country Status (7)

Country Link
US (2) US7674460B2 (de)
EP (1) EP1660010B1 (de)
JP (1) JP2007517763A (de)
AU (1) AU2004261260B2 (de)
ES (1) ES2426916T3 (de)
HK (1) HK1091141A1 (de)
WO (1) WO2005011590A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
WO2004078782A1 (en) * 2003-02-26 2004-09-16 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of b cells
JP2007517763A (ja) * 2003-08-01 2007-07-05 エイアンドジー ファーマスーティカル インコーポレイテッド Ｈｅｒ２アンタゴニストを用いた治療への感受性を回復させる組成物および方法
KR101229821B1 (ko) * 2010-11-09 2013-02-05 가톨릭대학교 산학협력단 그래뉼린-에피테린 전구체 유전자의 발현을 억제하는 안티센스 및 이를 함유하는 약제학적 조성물
EP3825327A1 (de) 2014-03-11 2021-05-26 Molecular Templates, Inc. Proteine mit bindungsregionen, shiga-toxin-a-untereinheiteffektorregionen und carboxyterminale, endoplasmatische retikulumlokalisierungssignalmotive
AU2015229583B2 (en) 2014-03-11 2020-07-09 Molecular Templates, Inc. Proteins comprising amino-terminal proximal Shiga toxin A Subunit effector regions and cell-targeting immunoglobulin-type binding regions
US20180104232A1 (en) * 2015-03-12 2018-04-19 The University Of Chicago Methods for determining prognosis for breast cancer patients
EP3660035A1 (de) 2015-05-30 2020-06-03 Molecular Templates, Inc. Deimmunisierte shigatoxin-a-untereinheitsgerüste und zellgerichtete moleküle damit
CA2991259A1 (en) 2015-07-26 2017-02-02 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20200024312A1 (en) 2017-01-25 2020-01-23 Molecular Templates, Inc. Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20210179733A1 (en) 2017-11-14 2021-06-17 Green Cross Lab Cell Corporation Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
MX2019009726A (es) 2018-04-17 2020-02-05 Molecular Templates Inc Moleculas con direccion hacia her2 que comprenden andamiajes de la sub-unidad a de la toxina shiga desinmunizados.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5789214A (en) 1988-03-08 1998-08-04 Novartis Finance Corporation Method of inducing gene transcription in a plant
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
DK0558676T3 (da) 1990-11-23 2000-09-25 Aventis Cropscience Nv Fremgangsmåde til transformering af enkimbladede planter
WO1993015195A1 (en) 1992-02-03 1993-08-05 Samuel Solomon Granulins from leukocytes
US5593874A (en) 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
ES2167373T3 (es) * 1993-08-09 2002-05-16 Edward Baral Un metodo para la sensibilizacion de celulas cancerosas con respecto a la lisis mediada por celulas asesinas.
WO1995014776A1 (en) * 1993-11-23 1995-06-01 Genentech, Inc. PROTEIN TYROSINE KINASES NAMED Rse
EP0731636B1 (de) * 1993-11-30 2006-01-11 Tanox, Inc. Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
US5693512A (en) 1996-03-01 1997-12-02 The Ohio State Research Foundation Method for transforming plant tissue by sonication
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US6881548B2 (en) 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6720159B1 (en) * 1997-12-16 2004-04-13 A&G Pharmaceutical, Inc. 88KDA tumorigenic growth factor and antagonists
US20030215445A1 (en) * 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
MXPA01008626A (es) * 1999-02-26 2002-04-24 Univ Johns Hopkins Inhibidor novedoso de muerte programada de celula.
WO2001064712A1 (en) * 2000-02-28 2001-09-07 The Regents Of The University Of California Methods for detection and treatment of neural cancers
ES2228932T3 (es) * 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
JP2004533206A (ja) 2000-10-11 2004-11-04 アバロン　ファーマシューティカルズ 化学療法のための標的としてのガン関連遺伝子
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
WO2004078782A1 (en) 2003-02-26 2004-09-16 A & G Pharmaceuticals, Inc. Methods for increasing the proliferation of b cells
WO2005000207A2 (en) 2003-05-30 2005-01-06 Medimmune, Inc. Pcdgf receptor antibodies and methods of use thereof
KR20060070491A (ko) * 2003-06-23 2006-06-23 에이 앤드 지 파마슈티컬즈, 인코포레이티드 항종양 요법에 대한 종양 세포의 감수성 회복 및 세포 사멸유도를 위한 조성물 및 방법
WO2005009217A2 (en) * 2003-07-21 2005-02-03 Medimmune, Inc. Diagnosis of pre-cancerous conditions using pcdgf agents
JP2007517763A (ja) * 2003-08-01 2007-07-05 エイアンドジー ファーマスーティカル インコーポレイテッド Ｈｅｒ２アンタゴニストを用いた治療への感受性を回復させる組成物および方法
WO2006044566A2 (en) 2004-10-13 2006-04-27 A & G Pharmaceutical, Inc. Autocrine growth factor receptors and methods

Also Published As

Publication number Publication date
US20050106150A1 (en) 2005-05-19
US20090010931A1 (en) 2009-01-08
WO2005011590A3 (en) 2007-09-20
AU2004261260B2 (en) 2011-01-27
US7674460B2 (en) 2010-03-09
JP2007517763A (ja) 2007-07-05
AU2004261260A1 (en) 2005-02-10
EP1660010B1 (de) 2013-07-24
EP1660010A4 (de) 2008-04-30
ES2426916T3 (es) 2013-10-25
WO2005011590A2 (en) 2005-02-10
EP1660010A2 (de) 2006-05-31
US7815906B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
HK1091141A1 (en) Compositions and methods for restoring sensitivity to treatment with her2 antagonists
IL175306A0 (en) Compositions and dosage forms for enhanced absorption
HK1180218A1 (en) Methods and compositions involving mda-7 mda-7
AP2089A (en) Compositions and methods for combination antiviraltherapy
GB0411940D0 (en) Methods and compositions
IL176259A0 (en) Compositions and methods for treating diabetes
IL176749A0 (en) ANTIBODIES TO MAdCAM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
HK1094203A1 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
EP1633718A4 (de) Zusammensetzungen und verfahren zur inhibierung von tgf-s
EP1638977A4 (de) Salinosporamide und anwendungsverfahren dafür
IL175179A0 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
IL178461A0 (en) Substituted 4-alkyl -and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
HK1088910A1 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
PL2215908T3 (pl) 2-alkilo-cykloalk(en)ylo-karboksamidy i ich zastosowanie jako fungicydów
IL184062A0 (en) Visco-supplement composition and methods
EP1731571A4 (de) Lösungsvermittler und zusammensetzung damit
GB0416252D0 (en) Cosmetic method and composition
ZA200508655B (en) Compositions and methods relating to stop-1
AU2003300904A8 (en) Antagonists for human prolactin
ZA200600473B (en) Salinosporamides and methods for use thereof
GB0327050D0 (en) Therapeutic methods compositions and uses
ZA200706038B (en) Visco-supplement composition and methods
PL114452U1 (en) Folding shield for loggia and balcony
GB0310251D0 (en) Therapeutic methods and compositions for use therein
GB0302801D0 (en) Therapeutic methods and compositions for use therein

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190728